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This study examines the clinical impact of PTEN genomic deletions using fluorescence in situ hybridisation (FISH) analysis of 107
prostate cancers, with follow-up information covering a period of up to 10 years. Tissue microarray analysis using interphase FISH
indicated that hemizygous PTEN losses were present in 42/107 (39%) of prostatic adenocarcinomas, with a homozygous PTEN
deletion observed in 5/107 (5%) tumours. FISH analysis using closely linked probes centromeric and telomeric to the PTEN indicated
that subband microdeletions accounted for B70% genomic losses. Kaplan–Meier survival analysis of PTEN genomic losses
(hemizygous and homozygous deletion vs not deleted) identified subgroups with different prognosis based on their time to
biochemical relapse after surgery, and demonstrated significant association between PTEN deletion and an earlier onset of disease
recurrence (as determined by prostate-specific antigen levels). Homozygous PTEN deletion was associated with a much earlier onset
of biochemical recurrence (P¼0.002). Furthermore, PTEN loss at the time of prostatectomy correlated with clinical parameters of
more advanced disease, such as extraprostatic extension and seminal vesicle invasion. Collectively, our data indicates that
haploinsufficiency or PTEN genomic loss is an indicator of more advanced disease at surgery, and is predictive of a shorter time to
biochemical recurrence of disease.
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Prostate cancer is the most commonly diagnosed malignancy in
men in the North America and the third leading cause of cancer-
related mortality after lung and colorectal cancer in males aged 40
years and older (Jemal et al, 2006). In spite of significant progress in
its clinical management, comparatively little is known about the
disease aetiology. Widely used biochemical, histopathological and
clinical criteria, for example prostate-specific antigen (PSA) level,
Gleason score, and the clinical tumour stage, have demonstrated a
significant variability in predicting subgroups of prostate cancer
patients with distinct clinical outcome (Miller et al, 2001; DeMarzo
et al, 2003; Glinsky et al, 2004). As such, there is an absolute
necessity to improve the current patient stratification methods
using biomarkers identified through studies of prostate cancer
genomics.
Previous cytogenetic and genomic profiling analyses have
identified several tumour-associated chromosomal rearrangements
in the initial stages of sporadic primary prostate cancer, consisting
predominantly of losses (Visakorpi et al, 1995; Verhagen et al, 2000;
Elo and Visakorpi, 2001). For example, well-recognised changes in
early prostatic carcinogenesis include loss of 8p, 6q, 10q, 13q, 16q
and 18q, and gain of 8q (Qian et al, 1998; Zitzelsberger et al, 2001;
Kasahara et al, 2002; Wolf et al, 2004; van Dekken et al, 2004;
Hughes et al, 2006; Ribeiro et al, 2006a,b). The importance of
genomic rearrangements in prostate cancer was emphasised by the
discovery of recurrent translocations in 40–60% of prostate
carcinoma and in 21% of the presumed premalignant lesion,
high-grade prostatic intraepithelial neoplasia (HPIN), involving the
TMPRSS2 gene with members of the erythroblast transformation-
specific (ETS) transcription factor family (Tomlins et al, 2005, 2006;
Ahlers and Figg, 2006; Cerveira et al, 2006; Perner et al, 2006; Soller
et al, 2006; Wang et al, 2006; Yoshimoto et al, 2006b). Indeed, HPIN
lesions reveal similar genetic features to those found in prostate
carcinomas, including the loss of 8p, gain of 8q (Hughes et al, 2006;
Ribeiro et al, 2006b), and genomic losses of chromosome 10
(Hughes et al, 2006; Ribeiro et al, 2006b). More detailed
investigation of the 10q losses using fluorescence in situ hybridisa-
tion (FISH) and tissue microarrays (TMAs) showed that PTEN
microdeletions were present in 68% of carcinomas and in 23% of
HPIN lesions found in radical prostatectomies. The detection of
PTEN deletion in HPIN suggested that somatic haploinsufficiency
per se might be an early pivotal step in the transition from HPIN to
invasive carcinoma (Yoshimoto et al, 2006a).
PTEN plays an important role in the modulation of the
phosphatidylinositol-3-kinase (PI3K) pathway by catalysing degra-
dation of phosphatidylinositol-(3,4,5)-trisphosphate generated by
PI3K (Besson et al, 1999). Phosphatidylinositol-(3,4,5)-trisphos-
phate activates the protein kinase Akt and its regulator PDK1
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s(Goberdhan and Wilson, 2003), which then modulates a number of
downstream targets with important roles in apoptosis and the cell-
cycle progression, including BAD (Datta et al, 1997), CASP3 and
CASP9 (Cardone et al, 1998), MDM2 (Ashcroft et al, 2002), mTOR
(Majumder et al, 2004), the forkhead family of transcription factors
(FKHR) (Brunet et al, 1999) and p27 (Graff et al, 2000). The lack of
inhibition of these pathways by PTEN inactivation is associated with
high Gleason score (Koksal et al, 2004) and tumour progression in
prostate cancer (Koksal et al, 2004; Bertram et al, 2006).
The occurrence of PTEN mutation in prostate cancer is
considered common, with reported frequencies (based on relatively
small sample sizes), ranging from 30 to 60% (Whang et al, 1998;
Kwabi-Addo et al, 2001). Given the high frequency of PTEN
inactivation by genomic deletion in prostate cancer using FISH
methods (Yoshimoto et al, 2006a), it has become more practical to
conduct much larger correlative studies of patient outcome in
situations when the PTEN gene is either lost, or retained in tumours.
Such findings would further implicate a role for PTEN haploinsuf-
ficiency in poor prognosis and tumour progression. Moreover,
knowledge of the PTEN deletion in the primary tumour, in addition
to current clinico-pathological features, might be of value when
selecting the optimum treatment for a particular patient.
MATERIALS AND METHODS
Tissue specimens
The collection of tissue specimens, clinical and follow-up data was
obtained and handled in accordance with the Hospital do Ca ˆncer
Research Ethics guidelines (Sa ˜o Paulo, Brazil). Archival formalin-
fixed, paraffin-embedded tissues were obtained from 107 radical
prostatectomies performed between 1997 and 2000 at the Hospital
do Ca ˆncer, AC Camargo, Sa ˜o Paulo, Brazil. For control purposes,
10 non-neoplastic prostate tissue samples were obtained from
patients undergoing surgery solely for benign prostate hyperplasia.
The prostate cancer cohort comprising 107 tumour samples and
control specimens were sampled using a 0.6mm diameter tissue
core distributed on TMA slide. Adjacent haematoxylin and eosin
(H&E)-stained section was reviewed by two pathologists to
determine the presence and extent of morphologically representa-
tive areas of the original tumours in each tissue core and Gleason
grading. The clinico-pathological (TNM) stage and Gleason scores
(range from 4 to 9) for each case were obtained from the medical
and surgical pathology reports. The size of tumour was based on
assessment of total surface area of the gland examined histologi-
cally involved by carcinoma. Preoperative PSA level was available
for all patients and the PSA non-failure was defined as PSA
remaining below 0.2ngml
 1 after radical prostatectomy. Recur-
rence-free interval was defined as the time between date of surgery
and the date of first PSA increase above 0.2ngml
 1.
A separate evaluation of PTEN deletion status was also
performed using a study group of clinically distinct prostate
cancers in which inclusion criteria were the availability of paraffin-
embedded formalin-fixed tissue from both an initial primary
adenocarcinoma surgical specimen and from metastatic prostate
adenocarcinoma in the regional lymph node metastases (Hospital
do Ca ˆncer, AC Camargo, Sa ˜o Paulo, Brazil). A cohort of 10 such
paired tumour samples were identified. Adjacent H&E-stained
section was reviewed by two pathologists to determine the
presence and extent of morphologically representative areas of
the original tumours in each tissue. Blood preoperative PSA levels
ranged from 10 to 84ngml
 1 within this cohort.
Follow-up studies
The 107 patients in the study group were followed up for a
period of up to 10 years subsequent to the initial surgery. The
median age at diagnosis was 63 years (range from 41 to 76). At the
end of the follow-up period for each patient, 58 (54%) had a
biochemical recurrence within the period of 0.79–86.28 months
after initial surgery. Metastatic progression occurred in 10 patients
at a median follow-up of 36.21 months from initial surgery.
Survival time for the remaining 49 disease-free cases varied from
13.85 to 127.60 months. The median overall survival for the entire
cohort of patients was 80.65 months. All relevant clinico-
pathological features of the 107-tumour cohort are summarised
in Table 1.
FISH
Dual-colour FISH on paraffin-embedded tumour tissue was
performed using commercially available DNA probes for cytoband
10q23 (Spectrum Orange PTEN locus-specific probe) and region
10p11.1-q11.1 (Spectrum Green centromere of chromosome 10
probe) (LSI PTEN/CEP 10 – Vysis Inc., Downers Grove, IL, USA).
The PTEN genomic probe spans 368kb and starts 166kb from 50
end of the gene and extends 98kb past the 30 end of the gene.
Histologic tissue sections of 5mm were deparaffinised with a series
of xylene before immersion in 100% ethanol. The slide was placed
in a 2 SSC solution at 751C for 20min, following by treatment in
0.25mgml
 1 Proteinase K (Roche Diagnostics, Indianapolis, IN,
USA) at 451C for 20min. The sections were dehydrated in a graded
series of ethanol, and washed in 2 SSC. Dual-colour probes and
target DNA were co-denatured at 801C for 10min. Post-hybridisa-
tion procedures were performed by 1.5 M urea/0.1 SSC solution
at 451C for 30min, 2 SSC and a graded ethanol series.
Sequential tri-colour FISH method was applied to the prostate
cancer TMA to map the flanking regions of genomic loss
associated with PTEN deletions in tumours. The following bacterial
artificial chromosome (BAC) clones were used. BACs located at:
(a) 10q23.2 (88.2–88.7Mb, 900kb upstream from the 50 PTEN gene
locus): RP11-141D8, RP11-52G13 and RP11-420K10; (b) 10q23.2
(89.4–89.5Mb, 100kb on the centromeric side of the 50 PTEN):
RP11-11O21; (c) 10q23.31 (89.6–89.7Mb, PTEN gene locus): RP11-
383D9; (d) 10q23.33 (96.2–96.6Mb, 6.6Mb on the telomeric side of
the 30 PTEN gene locus): RP11-119K6, RP11-90J1 and RP11-466J14;
(e) 10q25.1 (108.9–109.3Mb, 19.3Mb downstream from the 30
PTEN gene locus): RP11-246B13, RP11-49H17 and RP11-432B10.
The position and name of the BAC clones were taken from the
Human March 2006 assembly of the UCSC Genome Browser
1. DNA was extracted and labelled with either Spectrum
Green-dUTP, SpectrumOrange-dUTP (Vysis) or DEAC-dUTP
(PerkinElmer Life and Analytical Sciences, Boston, MA, USA)
using the Vysis nick-translation kit (Vysis). Labelling of probes
was done as described previously (Merscher et al, 1997; Sirvent
et al, 2000). The chromosome localisation of all BAC clones was
confirmed by both normal metaphase and tri-colour FISH analysis.
Data analysis
PTEN copy number was evaluated for each probe by counting
spots in a range from 50 to 100 non-overlapped, intact interphase
nuclei per tumour tissue core. 40,6-Diamidino-2-phenylindole,
dihydrochloride staining of nuclei with reference to the corre-
sponding H&E-stained tissue identified the areas of adenocarci-
noma. Based on hybridisation in 10 control cores (data not
shown), hemizygous deletion of PTEN were defined as 420%
(meanþ3 s.d. in non-neoplastic controls) of tumour nuclei
containing one PTEN locus signal and by the presence of CEP 10
signals. Homozygous deletion of PTEN was exhibited by the
simultaneous lack of the both PTEN locus signals and by the
presence of control signals (Mezzelani et al, 1999; Kawai et al,
2004; Korshunov et al, 2005; Ventura et al, 2006) in 430% of cells
(Korshunov et al, 2005).
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sStatistical analysis of PTEN deletion in 107-prostate cancer
TMA
Fluorescence in situ hybridisation findings for PTEN deletions
were correlated in a univariate and multivariate approaches with
clinical and pathologic features of disease aggressiveness. Initially,
presence and absence of deletion by FISH was correlated with
determinants of disease mortality and morbidity including PSA,
Gleason score and extraprostatic extension, as well as clinically
relevant end points such as time to biochemical relapse, and the
development time of metastases following the definitive treatment.
For prediction of 5-year biochemical risk failure, PTEN status (not
deleted, hemi- or homozygous deletion) was compared with all
relevant clinico-pathological features (Table 1). Univariate and
multivariate analyses of biochemical risk failure were studied by
Cox Proportional Hazard model (Tables 2 and 3, respectively). A
significant correlation between two parameters was taken at the
95% confidence interval. P-values o0.05 were considered sig-
nificant. In addition, the survival rate was estimated by applying
the Kaplan–Meier method. The end point for calculating the
survival time was defined by the time from radical prostatectomy
until the occurrence of metastasis or PSA determined by the
Table 1 Clinico-pathological parameters from 107 prostatic adenocarcinoma patients
PTEN
Clinico-pathological parameters Number of cases Not deleted Hemizygous Homozygous
Age median (min–max) 61.9 years (48–69)
Preoperative PSA (ngml
 1)
a P¼0.556
0.9–4.0 7 (6.7%) 3 (42.9%) 4 (57.1%) 0 (0%)
4.1–10.0 55 (52.3%) 32 (58.2%) 22 (40%) 1 (1.8%)
10.1–20.0 28 (26.7%) 19 (67.8%) 8 (28.6%) 1 (3.6%)
20.1–84.0 15 (14.3%) 6 (40%) 8 (53.3%) 1 (6.7%)
Median tumour volume (%)
a P¼0.158
0–10.0 32 (34%) 19 (59.4)% 13 (40.6%) 0 (0%)
10.1–20.0 19 (20.2%) 12 (63.2%) 7 (36.8%) 0 (0%)
20.1–85.0 43 (45.8%) 21 (48.9%) 17 (39.5%) 5 (11.6%)
Gleason score P¼0.142
Gleason 4–6 61 (57%) 39 (63.9%) 20 (32.8%) 2 (3.3%)
Gleason 7 33 (30.8%) 16 (48.48%) 16 (48.48%) 1 (3.03%)
Gleason 8–9 13 (12.2%) 5 (38.46%) 6 (46.15%) 2 (15.38%)
Pathologic stage P¼0.569
pT2a 6 (5.6%) 1 (16.7%) 5 (83.3%) 0 (0%)
pT2b 49 (45.8%) 30 (61.2%) 16 (32.7%) 3 (6.1%)
pT3a 32 (29.9%) 18 (56.2%) 13 (40.6%) 1 (3.1%)
pT3b 13 (12.2%) 4 (57.1%) 3 (42.9%) 0 (0%)
pT4 7 (6.5%) 4 (57.1%) 3 (42.9%) 0 (0%)
Seminal vesicle invasion P¼0.859
Negative 94 (87.9%) 53 (56.4%) 37 (39.4%) 4 (4.2%)
Positive 13 (12.1%) 7 (53.8%) 5 (38.5%) 1 (7.7%)
Perineural infiltration P¼0.517
Negative 15 (14.0%) 10 (66.7%) 5 (33.3%) 0 (0%)
Positive 92 (86%) 50 (54.4%) 37 (40.2%) 5 (4.4%)
Angiolymphatic invasion
a P¼0.346
Negative 78 (77.2%) 46 (59%) 29 (37.2%) 3 (3.8%)
Positive 23 (22.8%) 10 (43.5%) 11 (47.8%) 2 (8.7%)
Capsular invasion P¼0.729
Negative 46 (43%) 25 (54.4%) 18 (39.1%) 3 (6.5%)
Positive 61 (57%) 35 (57.4%) 24 (39.3%) 2 (3.3%)
Extraprostatic extension
a P¼0.713
Negative 83 (81.4%) 50 (60.2%) 30 (36.2%) 3 (3.6%)
Positive 19 (18.6%) 9 (47.4%) 8 (42.1%) 2 (10.5%)
Lymphonodal invasion
a P¼0.812
Negative 94 (95.9%) 54 (57.4%) 35 (37.2%) 5 (5.3%)
Positive 4 (4.1%) 2 (50%) 2 (50%) 0 (0%)
Biochemical recurrence P¼0.005
Negative 49 (46%) 35 (71.4%) 14 (28.6%) 0 (0%)
Positive 58 (54%) 25 (43.1%) 28 (48.3%) 5 (8.6%)
aValues not available for all 107 cases. Abbreviation: PSA, prostate-specific antigen. Median overall survival was 80.65 months. P-value¼w
2 analysis.
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changes with Gleason score was tested using Pearson’s w
2 statistic.
All calculations were performed using Stata 9.1.
RESULTS
PTEN deletion analysis in 107-prostate cancer TMA
To investigate whether loss of PTEN as determined by interphase
FISH indicated a greater prevalence in poor prognosis patients, the
frequency of PTEN deletion was investigated in the cohort of 107
tumour samples using a TMA in which anonymous annotation
codes allowed interrogation of clinical outcome parameters.
Hemizygous PTEN deletion was found in 42 of the 107 (39%)
adenocarcinomas samples. As shown in Table 4, homozygous
PTEN deletion was found in 5 of the 107 (5%) prostate
adenocarcinomas. Representative images of undeleted, hemizy-
gous and homozygous deletions are shown in Figure 1. Compre-
hensive FISH raw data sets for all samples is summarised in
Supplementary Table.
Among the hemizygous PTEN-deleted tumours detected from the
cohort of 107 adenocarcinomas, there were 42 patients with
hemizygous PTEN deletion that were classified as Gleason score
4–6 (20 tumours), 7 (16 tumours) and 8–9 (6 tumours). A median
tumour volume of 420% was found in 17 of the 42 adeno-
carcinomas. Biochemical recurrence based on PSA level was present
in 28 of 42 samples. A median tumour volume of 420% was found
in all five adenocarcinomas with homozygous PTEN deletion.
In addition, early biochemical recurrence was detected in all five of
these samples. A comprehensive description of the clinical
parameters associated with the adenocarcinomas having hemi-
zygous or homozygous PTEN deletion is summarised in Table 1.
Statistical analysis
After acquisition of FISH data, the 107 cases were reviewed to
search for potential associations between genomic loss of PTEN,
clinical variables of disease progression and tumour histology.
Univariate analysis of biochemical risk failure was significant for
perineural invasion, extraprostatic extension, seminal vesicle
invasion, Gleason score, preoperative PSA, lymph nodal invasion
and PTEN deletion (Table 2). For prediction of 5-year biochemical
risk failure by w
2 analysis, PTEN status (not deleted, hemi- or
homozygous deletion) was significantly associated with disease
recurrence based on PSA levels (Table 1). Other clinical
parameters of aggressive disease such as extraprostatic extension,
seminal vesicle and perineural invasion were also significantly
associated with biochemical recurrence. By multivariate analysis
(Table 3), PTEN deletion, extraprostatic extension and seminal
vesicle invasion were observed at an independent level to explain
biochemical failure. For comparison purpose, Kaplan–Meier
survival analysis applying established clinical markers, such as
the preoperative PSA, seminal vesicle invasion and surgical
margins status, was considered to identify subgroups with
different prognosis with respect to time of relapse after surgery.
The estimated disease-free survival curves demonstrated signifi-
cant association between PTEN deletion and short time based on
PSA recurrence intervals. Significantly homozygous PTEN deletion
in five tumours was associated with a much earlier onset of
biochemical recurrence based on PSA values (Figure 2).
Analysis of PTEN deletion in cohort of 10-paired primary
adenocarcinomas and metastatic prostate adenocarcinoma
in the regional lymph nodes
PTEN deletion frequency was determined by dual-colour FISH
using paired primary prostate adenocarcinomas and metastatic
adenocarcinoma in the regional lymph nodes derived from 10
patients. Overall, the presence of PTEN deletion was found at high
frequency (9 of 10) in both paired primary and metastatic lymph
Table 2 Univariate Cox proportional hazard analysis of biochemical
failure risks (each variable predictor analysed separately)
BRFS
Variables Category (5 years) P-value HR 95% CI
Perineural invasion Negative 86.67 0.0038 1 Reference
Positive 42.77 6.22 1.51–25.60
Extraprostatic Negative 56.71 0.0001 1 Reference
extension Positive 27.78 3.2 1.72–5.94
Seminal vesicle Negative 54.23 0.0001 1 Reference
invasion Positive 21.43 3.41 1.74–6.69
Gleason score 2–6 65.57 o0.0001 1 Reference
7 25.74 3.04 1.72–5.37
8–9 30.77 3.4 1.60–7.22
Preoperative PSA 0.9–4.0 67.69 o0.0001 1 Reference
4.1–10 58.36 1.98 0.47–8.41
10.1–20 51.74 2.38 0.54–10.42
20.1–84 6.67 10.27 2.30–45.87
Lymphonodal Negative 49.37 0.0068 1 Reference
invasion Positive 25.00 4.43 1.36–14.43
PTEN deletion Negative 58.68 0.0003 1 Reference
Hemizygous 40.3 1.78 1.03–3.05
Homozygous 0 6.15 2.26–16.73
Abbreviations: BRFS, biochemical recurrence free survival; CI, confidence interval; HR.
hazard ratio; PSA, prostate-specific antigen.
Table 3 Multivariate model to biochemical failure risks by Cox logistic
regression analysis
Variables Category HR P-value 95% CI
Extracapsular extension Negative 1 0.004 Reference
Positive 2.81 1.38–5.74
Seminal vesicle invasion Negative 1 0.019 Reference
Positive 2.8 1.18–6.65
PTEN deletion Negative 1 Reference
Hemizygous 1.96 0.022 1.10–3.49
Homozygous 11.26 0.002 2.44–51.93
Abbreviations: CI, confidence interval; HR, hazard ratio. Likelihood-ratio test
P¼0.0078.
Table 4 Analysis of PTEN gene copy number by FISH
PTEN locus Number of cases (%)
Hemizygous deletion
a 42 (39%)
Homozygous deletion
b 5 (5%)
Not deleted 60 (56%)
Abbreviation: FISH, fluorescence in situ hybridisation.
aHemizygous deletion of PTEN
was defined as 420% of tumour nuclei containing one PTEN locus signal (mean + 3
s.d. in non-neoplastic controls) (Korshunov et al, 2005).
bHomozygous deletions of
PTEN was identified by the simultaneous lack of both of the PTEN locus signals and by
the presence of CEP 10 signals in 430% of cells (Korshunov et al, 2005).
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one patient of the 10 retained both copies of the PTEN locus in his
primary tumour and in his metastatic lymph nodal biopsy.
Hemizygous PTEN deletion was found in both the primary and
the metastatic nodal tumour samples in four of 10 patients.
Homozygous PTEN deletion was found in both the primary
tumour and their metastatic lymph nodes in three of the 10
patients. Significantly, two of the 10 patients with a hemizygous
PTEN deletion in their primary adenocarcinomas, had positive
lymph node biopsies that had acquired a homozygous PTEN
deletion. These findings suggest that loss of the remaining PTEN
locus may be associated with metastasis.
Mapping the adjacent genomic regions deleted when PTEN
is lost
Tri-colour FISH using the BAC probes spanning the band 10q23.2,
50 flanking PTEN probe on the centromeric side of the locus, PTEN
locus (10pq23.31), and more telomeric probes mapping to
10q23.33 and 10q25.1, was performed on 10 of the 107
adenocarcinomas with hemizygous PTEN deletion and three of
the 107 adenocarcinomas with homozygous PTEN deletion
(Table 5). Sequential tri-colour FISH analyses from 7 of the 10
PTEN hemizygously deleted adenocarcinomas revealed BAC
probes either side of PTEN were retained as two copies, indicating
that a hemizygous PTEN deletion was usually accompanied by an
interstitial microdeletion within band 10q23.2–q23.31. Among the
three homozygous PTEN deletions, sequential tri-colour FISH
often revealed the hemizygous loss of the 10q23.2, 10q23.33 and
10q25.1 signals, and homozygous loss of the 50 flanking PTEN
genomic region and the PTEN locus signals.
DISCUSSION
The current challenge faced by prostate cancer researchers is to
discover the critical genes and cognate molecular pathways
responsible for the onset of neoplasia and disease progression,
as well as the development of novel therapeutic strategies based on
these discoveries. Initial progress in understanding the genetics of
this disease started with cytogenetic and genomic analyses of
primary prostate cancer tumours. Chromosomal losses of 10q
suggested that PTEN at cytoband 10q23.3 might be a tumour
suppressor gene involved in the development of prostate cancer
(Whang et al, 1998). More recently, a single-nucleotide poly-
morphism mapping array in prostate cancer (Liu et al, 2006) has
implicated the PTEN region to be the most frequently deleted in
prostate cancer. The reported frequency of PTEN deletion in
prostate cancer varies widely, most likely as a result of differences
in tissue preparation, stage of disease, and the methodology used
to detect molecular aberrations (Yoshimoto et al, 2006a). The
heterogeneous nature of these studies has potentially obscured the
clinical impact of PTEN loss in human prostate cancer. Our
findings using interphase FISH analysis of prostatic adenocarci-
noma TMAs have shown that PTEN deletion is an important event
in tumour progression of prostate cancer. The value of analysing
PTEN genomic losses by FISH methodologies is illustrated by its
ability to distinguish both deletion events associated with
homozygous PTEN losses in tumours. Moreover, our FISH analysis
is able to predict that 70% of hemizygous PTEN deletion will
involve an interstitial microdeletion within band 10q23.2–23.31
since flanking BAC probes were usually not deleted.
PTEN is a phosphoinositide 3-phosphatase which negatively
regulates the PI3K/AKT signalling pathway (Ohigashi et al, 2005).
Investigations to understand the role of PTEN loss have utilised a
well-characterised animal model of human prostate cancer
(Kwabi-Addo et al, 2001). Analysis of tumour progression in Pten
(þ/–) heterozygous mice, coupled with analysis of the PTEN gene
and protein in the resulting tumours, has shown that haploinsuf-
ficiency of the PTEN gene promotes instability and the progression
of prostate cancer (reviewed in Baker, 2007). Decreased PTEN
activity has also been identified in several human cancers
including prostate cancer (McMenamin et al, 1999; Koksal et al,
2004). A recent FISH and immunohistochemical PTEN analysis
Figure 1 PTEN probe enumeration and representative dual-colour FISH images are shown for prostate cancer TMA. (A) Digital images of H&E-stained
tissue microarray from 107 prostate cancer samples show areas of prostatic adenocarcinoma at low magnification and at  20 magnification (rectangle)
(ScanScopes System, Aperio Technologies, Inc., Vista, CA, USA). (B–D) A magnified H&E area is displayed in a tissue core with accompanying FISH for the
PTEN locus. The rectangles show the main FISH image high magnification. (B) The FISH image shows two signals of both red signals (10q23/PTEN locus) and
green signals (CEP 10) in most of the nuclei indicating no deletion of PTEN in tumour cells. (C) The FISH image shows tumour cells with single red signal for
10q23/PTEN locus in most of the nuclei and paired green signals for CEP 10 indicating hemizygous deletion of 10q23/PTEN locus in prostate cancer. (D)
Representative FISH image of homozygous deletion in prostate cancer shows absence of red signal for 10q23/PTEN locus in most of the nuclei and retained
green signals for CEP 10.
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frequency prostate cancer (Yoshimoto et al, 2006a). Other studies
have demonstrated an association between decreased PTEN
protein expression and a higher Gleason grade and advanced
tumour stage (McMenamin et al, 1999; Koksal et al, 2004; Schmitz
et al, 2007). Recently, complete loss of PTEN expression was
observed in 26 of 112 (23%) of prostate cancer patients at the time
of first diagnosis (Schmitz et al, 2007). Moreover, it was reported
that 25 of 42 (59%) of both the neoplastic prostate glands and the
invasive prostatic adenocarcinomas cells in the lymph node
showed complete lack of PTEN expression, and of these 52%
exhibited already loss of PTEN expression at first diagnosis. To
determine whether PTEN genomic losses were also more prevalent
in metastatic disease, as predicted by the above reports, we
selected a small cohort of paired primary prostate adenocarcino-
mas and metastatic adenocarcinoma in the regional lymph nodes
derived from the same patient. A very high frequency (90%) of
PTEN deletion was evident in this study group, consistent with
notion that loss of PTEN function is generally associated with
more aggressive disease. Interestingly, two patients with hemi-
zygous deletions in their primary tumours had homozygous
deletions in their matched nodal metastatic sample. These data are
in keeping with the idea that complete loss of PTEN function is
associated with transition to more progressive disease (Verhagen
et al, 2006; Schmitz et al, 2007).
In this study, we also demonstrate that both hemi- and
homozygous PTEN loss is a highly significant prognostic marker
for poor clinical outcome in prostate cancer. Prediction of 5-year
biochemical risk failure analysis showed that PTEN status (not
deleted, hemi- or homozygous deletion) correlated specifically
with biochemical recurrence based on PSA levels. Our findings
show a strong association between PTEN deletion and a shorter
time interval to PSA recurrence. Significantly, homozygous PTEN
deletion in five tumours was associated with a much earlier onset
of biochemical recurrence based on PSA values. These tumours
also had a median tumour volume typically 420%. Similar to the
findings of (Schmitz et al, 2007) PTEN loss was not associated with
Gleason score (Pearson’s w
2 test, P¼0.142). However, the absence
of a statistical relationship in our study may have arisen because of
the relatively small distribution of different Gleason scores in our
cohort.
These novel findings implicate further an early role for PTEN
haploinsufficiency and poor clinical outcome in prostate cancer.
Our studies have demonstrated that the presence of PTEN genomic
losses are frequent at diagnosis and are a significant prognostic
marker for the subsequent development of clinically advanced
disease. Previously, PTEN inactivation has been primarily been
detected in locally advanced (Whang et al, 1998) or metastatic
prostate cancer (Schmitz et al, 2007). Our new findings suggest
that the acquisition of the deletion and concomitant loss of PTEN
functional activity at an earlier phase in prostatic oncogenesis is an
important determinant of the molecular pathways that govern a
more aggressive tumour phenotype. Knowledge of the pathways
downstream to PTEN and the genomic status of the PTEN gene in
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Figure 2 Kaplan–Meier curves illustrating biochemical recurrence-free
survival among 107 prostate cancer patients defined by the status of
selected clinico-pathological parameters and PTEN copy number changes.
(A) PSA recurrence-free survival curve stratified by the PTEN locus copy
number changes on prostate cancer patients. (B) PSA recurrence-free
survival analysis stratified by seminal vesicle invasion on prostate cancer
patients. (C) PSA recurrence-free survival analysis stratified by surgical
margins on prostate cancer patients.
Table 5 Mapping the adjacent genomic regions deleted when PTEN is
lost using BAC DNA probes spanning the predicted deletion interval on
chromosome 10q
TMA
Centromeric
to PTEN
a
50 flanking
PTEN
b PTEN
c
Telomeric
to PTEN
d
Telomeric
to PTEN
e
Predicted
deletion
19 +/+ +/  +/  +/+ +/+ Microdeletion
29 +/  +/  +/  +/+ +/+ Small
35 +/  +/  +/  +/+ +/+ Small
38 +/+ +/  +/  +/+ +/+ Microdeletion
39 +/+ +/  +/  +/+ +/+ Microdeletion
41 +/+ +/  +/  +/+ +/+ Microdeletion
46 +/+ +/  +/  +/+ +/+ Microdeletion
49 +/+ +/  +/  +/+ +/+ Microdeletion
91 +/+ +/  +/  +/  +/+ Large
184 +/+ +/  +/  +/+ +/+ Microdeletion
28 +/   /   /  +/  +/  Microdeletion
f
large
g
72 +/+  /   /  +/+ +/+ Microdeletion
88 +/   /   /  +/  +/  Microdeletion
f
Large
g
Abbreviations: BAC, bacterial artificial chromosome; FISH, fluorescence in situ
hybridisation. The summarised FISH analysis described the findings from the largest
clonal cell population. +/+ no copy change; +/  hemizygous deletion;  / 
homozygous deletion. Estimated microdeletion: B200kb. Estimated small deletion:
B7–8Mb. Estimated large deletion: B19–21Mb.
a10q23.2 (88.2–88.6Mb).
b10q23.2 (89.4–89.5Mb).
cPTEN locus (89.6–89.7Mb).
d10q23.33 (96.2–
96.6Mb).
e10q25.1 (108.9–109.3Mb).
fFirst event.
gSecond event.
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stumours must be considered in the design of future therapeutic
trials of prostate cancer.
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